ALL: Which Life-Saving Tx Is Best? ALL: Which Life-Saving Tx Is Best?
New treatments like bispecific antibodies and CAR T-cell therapy have helped many patients with relapsed/refractory acute lymphoblastic leukemia live longer but which is best?MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2024 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New study paves the way for precision drugs to treat blood cancers
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive activation and cytokine-independent signaling and underlie several hematological malignancies from myeloproliferative neoplasms (MPN) to acute leukemia and lymphomas. JAK2 contains an active kinase domain and an inactive pseudokinase domain. Interestingly, pathogenic mutations mainly occur in the regulatory pseudokinase domain. (Source: World Pharma News)
Source: World Pharma News - April 4, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
DUBLIN, March 29, 2024 /PRNewswire/ -- The "Global Acute Lymphoblastic Leukemia Therapeutics Market: Focus on Cell Type, Therapy Type, and Over 10 Countries' Data - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering. The global market for Acute... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 29, 2024 Category: Pharmaceuticals Tags: MRR Source Type: news
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
THURSDAY, March 28, 2024 -- For older patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), posttransplant outcomes have improved over time, according to a study published online March 22 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2024 Category: Pharmaceuticals Source Type: news
Breastfeeding Tied to Reduced Childhood Leukemia Risk
(MedPage Today) -- Longer duration of exclusive breastfeeding was associated with a reduced risk of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to results from a Danish population-based cohort study.
Compared with... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 27, 2024 Category: Hematology Source Type: news
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
WALTHAM, Mass., March 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 26, 2024 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Frontline Regimen for Aggressive ALL
(MedPage Today) -- The FDA granted accelerated approval to ponatinib (Iclusig) in combination with chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in previously untreated adults, the agency announced this... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 22, 2024 Category: American Health Source Type: news
Predicting Risk for Secondary Leukemia after PARPi Therapy Predicting Risk for Secondary Leukemia after PARPi Therapy
A new study pinpointed potential predictive factors for secondary myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor therapy in women with ovarian cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 22, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
FDA Approves Ponatinib for Upfront Ph+ ALL FDA Approves Ponatinib for Upfront Ph+ ALL
This is the first targeted treatment approved for upfront use in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 20, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
FDA grants accelerated approval to ponatinib with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
On March 19, 2024, the Food and Drug Administration granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) with chemotherapy f (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 19, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Besponsa (inotuzumab ozogamicin) for Pediatric Patients with Acute Lymphoblastic Leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
Efficacy was... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 6, 2024 Category: Drugs & Pharmacology Source Type: news
All-Oral AML Regimen Shows Promise for Older, Unfit Patients
(MedPage Today) -- An all-oral combination of decitabine-cedazuridine (Inqovi) plus venetoclax (Venclexta) was active and safe in older or unfit acute myeloid leukemia (AML) patients deemed ineligible for intensive chemotherapy, results of a phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 5, 2024 Category: Hematology Source Type: news
Man in remission from blood cancer and HIV after remarkable treatment
Paul Edmonds of California is fifth-known person in world confirmed to be in remission from both, says cancer instituteDoctors say a man inCalifornia who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.Paul Edmonds is only the fifth-known person in the world confirmed to be in remission for both acute myelogenous leukemia and HIV, according to a recentnews release from City of Hope, the national cancer institute that provided his medical care.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 28, 2024 Category: Science Authors: Ramon Antonio Vargas Tags: US news Infectious diseases Medical research Aids and HIV Cancer research California World news Science Source Type: news
Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
WEDNESDAY, Feb. 21, 2024 -- For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the February issue of Leukemia Research.
Hannah Goulart,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2024 Category: Pharmaceuticals Source Type: news
